Charles River Laboratories launched its lentiviral vector (LVV) manufacturing platform, Lentivation. The platform has the capability to reduce LVV manufacturing timelines for gene and gene-modified cell therapies by up to 60 percent, translating to fewer than seven months compared to traditional manufacturing workflows.

Lentivation leverages Charles River’s screening toolbox for tackling challenging gene-of-interest plasmids, off-the-shelf (OTS) LVV packaging plasmids, phase-appropriate production with fit-for-purpose facilities, on-hand materials, and in-house analytics.

Charles River has standardized protocols for cell culture, transfection, and downstream purification. These high-yield, optimized methods increase speed to clinical manufacturing by reducing process development time and costs while ensuring high quality production, according to the company.

The addition of Lentivation follows the launch of Charles River’s OTS LVV packaging and AAV pHelper plasmids, andmeXpDNA plasmid manufacturing platform, aimed at supporting both LVV-based and AAV-based gene therapy programs. Lentivation also complements the nAAVigation platform announced previously, further bolstering Charles River’s cell and gene therapy manufacturing capabilities.

“We are thrilled to add the Lentivation platform to our robust portfolio of existing capabilities,” said Kerstin Dolph, corporate senior vice president, biologics solutions, Charles River. “Our LVV manufacturing offerings allow us to further support advanced therapy programs and, most importantly, deliver novel gene therapies to patients across the globe.”